Skip to main content
Publications
Tam S, Neslund-Dudas C, Barrett AM , Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis . Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Pesantez D, Hoorn ST, Machado I, Garcia-Albeniz X , Rodriguez-Salas N, Heredia-Soto V, Vinal D, Pericay C, Garcia-Carbonero R, Losa F, Alonso V, Vera R, Batlle JF, Gallego J, Salud A, Nogue M, Layos L, Montagut C, Capdevila J, Vermeulen L, Maurel J, Fernandez-Martos C. Total neoadjuvant therapy with or without aflibercept in rectal cancer: three-year results of GEMCAD-1402 . J Natl Cancer Inst. 2023 Dec 6;115(12):1497-505. doi: 10.1093/jnci/djad120
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J , Bennett L , Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma . Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
Garcia-Albeniz X , Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02) . Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J , Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. Individual trade‐offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma . Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257
Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Perez-Carrion R, Carmona A, Ayuso JR, Ripolles T, Bouzas R, Gironella M, Garcia-Albeniz X , Feliu J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial . Tumour Biol. 2017 Jun;39(6). doi: 10.1177/1010428317705509
Pavlovic M, Arnal-Estape A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albeniz X , Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis RR. Enhanced MAF oncogene expression and breast cancer bone metastasis . J Natl Cancer Inst. 2015 Sep 15;107(12):djv256. doi: 10.1093/jnci/djv256
Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA , Morea J, Simon L, Strand CV, Williams DA. Fibromyalgia syndrome module at OMERACT 9: domain construct . J Rheumatol. 2009 Oct 1;36(10):2318-29.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin SA . OMERACT 8 workshop: fibromyalgia syndrome . J Rheumatol. 2007 Jun;34(6):1415-25.
Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA , Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascon P, Mellado B, Molina R. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients . Tumour Biol. 2007;28(5):264-82.